Heron (HRTX) Price to Earnings Ratio

Heron Therapeutics, Inc. - graphic logo of issuer HRTX

Heron Therapeutics (HRTX) carries out commercial drug production through certified plants in Europe and the US, which is supported by the price visualization with the -2.40 indicator used in the asset's base valuation. The company generates revenue from chemotherapy-induced nausea treatments and post-operative pain management. Currently, the business is focusing on optimizing distribution and expanding partnerships to achieve full payback.

Heron (HRTX) - Price to Earnings Ratio from 07/04/2022 to 11/17/2026

Comprehensive metric breakdowns and analytics for herontx.com (HRTX)

- price and consensus price forecast:
Comprehensive company analysis:HRTX (Heron)
Product sample of Heron Therapeutics

The stability of drug supplies through the network of contract manufacturing plants and warehouses of Heron Therapeutics (HRTX) is reflected in the company's monthly P/E dynamics. This ratio determines the degree of asset overvaluation by comparing the market value of the business with its actual profitability. The metric is calculated as the ratio of the current share price to the net earnings per share. This allows a conservative investor to assess the fundamental fairness of the price and minimize the risks of entering an overheated asset.